Mads Hald Andersen

Mads Hald Andersen is a prominent figure in cancer immunotherapy research and a leader in the field. He is the Director and Professor at the Center for Cancer Immune Therapy (CCIT) at Herlev University Hospital in Denmark.14

Academic Background and Achievements

Professor Andersen has an impressive academic background:

• He obtained his DScTech (Doctor of Technical Sciences) in 2006
• He earned his DMSc (Doctor of Medical Sciences) in 20161

Throughout his career, Professor Andersen has received several prestigious awards, including:

• The Lundbeck Foundation research prize (2012)
• The Danish Cancer Society Research Award (2006)
• The Hallas-Møller Stipend (2007)1

Research Focus and Contributions

Professor Andersen's research primarily focuses on characterizing natural immune responses to malignant cells.3 His work has led to significant advancements in the field of cancer immunotherapy:

• He has identified several T-cell antigens, including survivin, the Bcl-2 family, and RhoC
• These discoveries have formed the basis for ongoing clinical trials in Europe and the USA
• Survivin, one of his identified antigens, is now one of the most commonly used cancer antigens worldwide1

Recently, Professor Andersen initiated a new research program focusing on antigen-specific immune regulation, specifically studying IDO and PD-L1.1

Professional Experience and Roles

• 2015-present: Professor at Copenhagen University2
• 2006-present: Vice-Director and co-Founder of the Center for Cancer Immunotherapy (CCIT) at the University Hospital Herlev2
• He has considerable pharmaceutical experience and has founded several biotech companies, including IO Biotech Aps1

Publications and Patents

Professor Andersen has an extensive publication record:

• Over 150 publications in peer-reviewed journals
• More than 15 patents
• Several book chapters1

His work has garnered significant attention in both scientific and popular media, with his publications often accompanied by commentaries and articles.1